Tech community "dumbfounded" by Mnuchin's dismissal of AI impact on jobs

Gilead's top executives continue to reap the benefits of the blockbuster hepatitis C drugs it acquired several years ago. Those figures represent the actual value of stock vested in 2016, not estimated fair value. Milligan took over as CEO in March 2016, replacing Martin, who now serves as executive chairman. Martin has taken home $523 million since 2014, when Gilead started selling both of its hepatitis C drugs, Sovaldi and Harvoni. A vast majority of Martin's pay has come in the form of cashed-in stock.